{"id":1340,"date":"2023-09-08T18:41:12","date_gmt":"2023-09-08T21:41:12","guid":{"rendered":"https:\/\/www.pint-pharma.com\/portal\/?page_id=1340"},"modified":"2023-09-08T18:55:48","modified_gmt":"2023-09-08T21:55:48","slug":"news-pint","status":"publish","type":"page","link":"https:\/\/www.pint-pharma.com\/portal\/news-pint\/","title":{"rendered":"News Pint"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"1340\" class=\"elementor elementor-1340\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-99c2f28 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"99c2f28\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-3b147ec\" data-id=\"3b147ec\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-56d33e2 elementor-widget elementor-widget-heading\" data-id=\"56d33e2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">News<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-9ae7b16 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"9ae7b16\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-b94ddb1\" data-id=\"b94ddb1\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-142ab76 elementor-grid-eael-col-4 elementor-grid-tablet-eael-col-2 elementor-grid-mobile-eael-col-1 elementor-widget elementor-widget-eael-post-grid\" data-id=\"142ab76\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;eael_post_grid_columns&quot;:&quot;eael-col-4&quot;,&quot;eael_post_grid_columns_tablet&quot;:&quot;eael-col-2&quot;,&quot;eael_post_grid_columns_mobile&quot;:&quot;eael-col-1&quot;}\" data-widget_type=\"eael-post-grid.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div id=\"eael-post-grid-142ab76\" class=\"eael-post-grid-container\">\n            <div class=\"eael-post-grid eael-post-appender eael-post-appender-142ab76 eael-post-grid-style-one\" data-layout-mode=\"masonry\"><article class=\"eael-grid-post  eael-post-grid-column eael-pg-post-1915 category-sem-categoria\" data-id=\"1915\">\n        <div class=\"eael-grid-post-holder\">\n            <div class=\"eael-grid-post-holder-inner\"><div class=\"eael-entry-wrapper\"><header class=\"eael-entry-header\"><h2 class=\"eael-entry-title\"><a class=\"eael-grid-post-link\" href=\"https:\/\/www.pint-pharma.com\/portal\/pint-pharma-announces-invimas-approval-of-orladeyo-berotralstat-the-first-oral-therapy-for-preventing-hereditary-angioedema-hae-attacks-in-patients-aged-12-and-older-in-colombia\/\" title=\"Pint Pharma Announces INVIMA\u2019s Approval of ORLADEYO\u00ae (berotralstat), the First Oral Therapy for Preventing Hereditary Angioedema (HAE) Attacks in Patients Aged 12 and Older in Colombia\">Pint Pharma Announces INVIMA\u2019s Approval of ORLADEYO\u00ae (berotralstat), the First Oral Therapy for Preventing Hereditary Angioedema (HAE) Attacks in Patients Aged 12 and Older in Colombia<\/a><\/h2><\/header><div class=\"eael-entry-content\">\n                        <div class=\"eael-grid-post-excerpt\"><p>Pint Pharma Announces INVIMA\u2019s Approval of ORLADEYO\u00ae (berotralstat), the First...<\/p><a href=\"https:\/\/www.pint-pharma.com\/portal\/pint-pharma-announces-invimas-approval-of-orladeyo-berotralstat-the-first-oral-therapy-for-preventing-hereditary-angioedema-hae-attacks-in-patients-aged-12-and-older-in-colombia\/\" class=\"eael-post-elements-readmore-btn\">Ler mais<\/a><\/div>\n                    <\/div><div class=\"eael-entry-footer\"><div class=\"eael-entry-meta\"><span class=\"eael-posted-on\"><time datetime=\"2025-06-26\">2025-06-26<\/time><\/span><\/div><\/div><\/div><\/div>\n        <\/div>\n    <\/article><article class=\"eael-grid-post  eael-post-grid-column eael-pg-post-1880 category-sem-categoria\" data-id=\"1880\">\n        <div class=\"eael-grid-post-holder\">\n            <div class=\"eael-grid-post-holder-inner\"><div class=\"eael-entry-media\"><div class=\"eael-entry-overlay fade-in\"><i class=\"fas fa-long-arrow-alt-right\" aria-hidden=\"true\"><\/i><a href=\"https:\/\/www.pint-pharma.com\/portal\/pint-pharma-announces-anvisas-approval-of-besremi-ropeginterferon-alfa-2b-for-the-treatment-of-polycythemia-vera\/\"><\/a><\/div><div class=\"eael-entry-thumbnail \">\n                <img decoding=\"async\" width=\"150\" height=\"150\" src=\"https:\/\/www.pint-pharma.com\/portal\/wp-content\/uploads\/2025\/03\/Besremi_image-150x150.jpg\" class=\"attachment-thumbnail size-thumbnail wp-image-1882\" alt=\"\" \/>\n            <\/div>\n        <\/div><div class=\"eael-entry-wrapper\"><header class=\"eael-entry-header\"><h2 class=\"eael-entry-title\"><a class=\"eael-grid-post-link\" href=\"https:\/\/www.pint-pharma.com\/portal\/pint-pharma-announces-anvisas-approval-of-besremi-ropeginterferon-alfa-2b-for-the-treatment-of-polycythemia-vera\/\" title=\"Pint Pharma Announces ANVISA\u2019s Approval of BESREMi\u00ae (ropeginterferon alfa-2b) for the Treatment of Polycythemia Vera\">Pint Pharma Announces ANVISA\u2019s Approval of BESREMi\u00ae (ropeginterferon alfa-2b) for the Treatment of Polycythemia Vera<\/a><\/h2><\/header><div class=\"eael-entry-content\">\n                        <div class=\"eael-grid-post-excerpt\"><p>Pint Pharma and PharmaEssentia announced today that ANVISA (Brazilian Health...<\/p><a href=\"https:\/\/www.pint-pharma.com\/portal\/pint-pharma-announces-anvisas-approval-of-besremi-ropeginterferon-alfa-2b-for-the-treatment-of-polycythemia-vera\/\" class=\"eael-post-elements-readmore-btn\">Ler mais<\/a><\/div>\n                    <\/div><div class=\"eael-entry-footer\"><div class=\"eael-entry-meta\"><span class=\"eael-posted-on\"><time datetime=\"2025-03-21\">2025-03-21<\/time><\/span><\/div><\/div><\/div><\/div>\n        <\/div>\n    <\/article><article class=\"eael-grid-post  eael-post-grid-column eael-pg-post-1829 category-sem-categoria\" data-id=\"1829\">\n        <div class=\"eael-grid-post-holder\">\n            <div class=\"eael-grid-post-holder-inner\"><div class=\"eael-entry-wrapper\"><header class=\"eael-entry-header\"><h2 class=\"eael-entry-title\"><a class=\"eael-grid-post-link\" href=\"https:\/\/www.pint-pharma.com\/portal\/pint-pharma-anuncia-la-aprobacion-de-orladeyo-berotralstat-la-primera-terapia-oral-indicada-para-prevenir-los-ataques-de-angioedema-hereditario-hae-en-pacientes-adultos-y-pediatricos-de-12\/\" title=\"Pint Pharma anuncia la aprobaci\u00f3n de ORLADEYO\u00ae (berotralstat), la primera terapia oral indicada para prevenir los ataques de angioedema hereditario (HAE) en pacientes adultos y pedi\u00e1tricos de 12 a\u00f1os en adelante en Peru.\">Pint Pharma anuncia la aprobaci\u00f3n de ORLADEYO\u00ae (berotralstat), la primera terapia oral indicada para prevenir los ataques de angioedema hereditario (HAE) en pacientes adultos y pedi\u00e1tricos de 12 a\u00f1os en adelante en Peru.<\/a><\/h2><\/header><div class=\"eael-entry-content\">\n                        <div class=\"eael-grid-post-excerpt\"><p>Pint Pharma anuncia la aprobaci\u00f3n de ORLADEYO\u00ae (berotralstat), la primera...<\/p><a href=\"https:\/\/www.pint-pharma.com\/portal\/pint-pharma-anuncia-la-aprobacion-de-orladeyo-berotralstat-la-primera-terapia-oral-indicada-para-prevenir-los-ataques-de-angioedema-hereditario-hae-en-pacientes-adultos-y-pediatricos-de-12\/\" class=\"eael-post-elements-readmore-btn\">Ler mais<\/a><\/div>\n                    <\/div><div class=\"eael-entry-footer\"><div class=\"eael-entry-meta\"><span class=\"eael-posted-on\"><time datetime=\"2024-07-10\">2024-07-10<\/time><\/span><\/div><\/div><\/div><\/div>\n        <\/div>\n    <\/article><article class=\"eael-grid-post  eael-post-grid-column eael-pg-post-1791 category-sem-categoria\" data-id=\"1791\">\n        <div class=\"eael-grid-post-holder\">\n            <div class=\"eael-grid-post-holder-inner\"><div class=\"eael-entry-wrapper\"><header class=\"eael-entry-header\"><h2 class=\"eael-entry-title\"><a class=\"eael-grid-post-link\" href=\"https:\/\/www.pint-pharma.com\/portal\/pint-pharma-anuncia-la-aprobacion-de-orladeyo\/\" title=\"Pint Pharma anuncia la aprobaci\u00f3n de ORLADEYO\u00ae (berotralstat), la primera terapia oral indicada para prevenir los ataques de angioedema hereditario (HAE) en pacientes adultos y pedi\u00e1tricos de 12 a\u00f1os en adelante en Mexico.\">Pint Pharma anuncia la aprobaci\u00f3n de ORLADEYO\u00ae (berotralstat), la primera terapia oral indicada para prevenir los ataques de angioedema hereditario (HAE) en pacientes adultos y pedi\u00e1tricos de 12 a\u00f1os en adelante en Mexico.<\/a><\/h2><\/header><div class=\"eael-entry-content\">\n                        <div class=\"eael-grid-post-excerpt\"><p>May 13, 2024 06:23 PM Eastern Daylight Time Ciudad de...<\/p><a href=\"https:\/\/www.pint-pharma.com\/portal\/pint-pharma-anuncia-la-aprobacion-de-orladeyo\/\" class=\"eael-post-elements-readmore-btn\">Ler mais<\/a><\/div>\n                    <\/div><div class=\"eael-entry-footer\"><div class=\"eael-entry-meta\"><span class=\"eael-posted-on\"><time datetime=\"2024-05-15\">2024-05-15<\/time><\/span><\/div><\/div><\/div><\/div>\n        <\/div>\n    <\/article><\/div>\n            <div class=\"clearfix\"><\/div>\n        <\/div>            <div class=\"eael-load-more-button-wrap eael-force-hide\">\n                <button class=\"eael-load-more-button\" id=\"eael-load-more-btn-142ab76\" data-widget-id=\"142ab76\" data-widget=\"142ab76\" data-page-id=\"1340\" data-template=\"{&quot;dir&quot;:&quot;lite&quot;,&quot;file_name&quot;:&quot;one.php&quot;,&quot;name&quot;:&quot;Post-Grid&quot;}\" data-class=\"Essential_Addons_Elementor\\Elements\\Post_Grid\" data-layout=\"masonry\" data-page=\"1\" data-args=\"orderby=date&amp;order=desc&amp;ignore_sticky_posts=1&amp;post_status=publish&amp;posts_per_page=4&amp;offset=0&amp;post_type=post&amp;eael_args_sig=e7b888146888eb97a50cb27df11b7d81ad5f8199950bfbe1a6db203c6611a5ee\" data-max-page=\"3\">\n                    <span class=\"eael-btn-loader button__loader\"><\/span>\n                    <span class=\"eael_load_more_text\">Carregar mais<\/span>\n                <\/button>\n            <\/div>\n            \t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-2a55be1 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"2a55be1\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-2150a4b\" data-id=\"2150a4b\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-cb451e3 elementor-widget elementor-widget-spacer\" data-id=\"cb451e3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>News BRIEF-Puma Biotechnology And Pint Pharma Enter Licensing Agreement To Commercialize Nerlynx In Latin America By&nbsp;Reuters Staff BRIEF-Puma Biotechnology And Pint Pharma Enter Licensing Agreement&#8230; Ler mais 8 de setembro de 2023 BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO\u00ae (berotralstat) in Latin America BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO\u00ae (berotralstat)&#8230; [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-1340","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.pint-pharma.com\/portal\/wp-json\/wp\/v2\/pages\/1340","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pint-pharma.com\/portal\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.pint-pharma.com\/portal\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.pint-pharma.com\/portal\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pint-pharma.com\/portal\/wp-json\/wp\/v2\/comments?post=1340"}],"version-history":[{"count":0,"href":"https:\/\/www.pint-pharma.com\/portal\/wp-json\/wp\/v2\/pages\/1340\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.pint-pharma.com\/portal\/wp-json\/wp\/v2\/media?parent=1340"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}